Also, EpCAM is subjected to regulated proteolytic cleavage and the majority of antibodies that recognize EpCAM on cancer cells target the terminal (signal peptide) part of the extracellular domain that can be cleaved off [14]. This evidence concerns the gene EPCAM and cancer.